Aveo Pharmaceuticals, Inc.

Mersana Therapeutics, Inc.

Laura L Poling

William M Winston, Jr

Ting Chen

Jeno Gyuris

Ailin Bai

Solly Weiler

Zhigang Weng

Maria Isabel Chiu

Lorena Lerner

Sandra Abbott

Qing Liu

Nianjun Tao

Alisa C Bell

Heidi Okamura

Donald A Bergstrom

Timothy B Lowinger

Aleksandr V Yurkovetskiy

Peter U Park

Natalya D Bodyak

Rebecca Mosher

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.

Anti-Notch3 antibody

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Anti-GDF-15 antibodies

This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).

Compositions and methods for predicting response to NaPi2b-targeted therapy

This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

NaPi2b-targeted antibody-drug conjugates and methods of use thereof

Anti-GDF15 antibodies

Methods of treatment using anti-GDF15 antibodies

Growing community of inventors

Acton, MA, United States of America

Laura L Poling